Initial response to portoenterostomy determines long-term outcome in patients with biliary atresia

J Pediatr Surg. 2000 Apr;35(4):593-7. doi: 10.1053/jpsu.2000.0350593.

Abstract

Purpose: The aim of this study was to assess the efficacy of portoenterostomy in biliary atresia and determine factors that predict outcomes.

Methods: The outcomes after portoenterostomy for biliary atresia from 1976 to 1996 were graded into 3 defined groups: G (good, jaundice free); I (intermediate, progressive liver disease with liver transplant if needed after 3 years of age); P (poor, liver transplant or death at less than 3 years of age).

Results: Twenty-seven of 49 children (55%) who underwent portoenterostomy responded. Of these, 13 (26%) were jaundice free (G). Of 14 children (28%) in I, 6 underwent liver transplant after 3 years of age. Of 22 children (44.8%) in P, 14 (28%) died before 3 years and 8 underwent liver transplant before 3 years. Thus, 42% of the children in this series are surviving with native liver. Age at operation in P was significantly different compared with G. Preoperative values of bilirubin and alanine transaminase were comparable in the 3 groups. Postoperative values of bilirubin and alanine transaminase were lower in G and I compared with P Complications were significantly lower in group G.

Conclusions: Portoenterostomy alone in biliary atresia is beneficial in 40% of cases. Factors associated with the outcome include age at operation, postoperative cholangitis, and change in values of bilirubin and alanine transaminase. A classification based on decline of bilirubin and enzyme levels 3 months after portoenterostomy is proposed to predict the long-term outcome of an individual case of biliary atresia. It is particularly relevant in the intermediate group in which timing of referral may preclude or compromise liver transplant.

MeSH terms

  • Alanine Transaminase / blood
  • Biliary Atresia / blood
  • Biliary Atresia / surgery*
  • Child
  • Humans
  • Liver Transplantation
  • Portoenterostomy, Hepatic*
  • Treatment Outcome

Substances

  • Alanine Transaminase